ADAC’s Q1 profits and revenues surge
Nuclear medicine vendor ADAC Laboratories enjoyed a banner firstquarter of fiscal 1997 (end-December). The Milpitas, CA, firmlast week reported quarterly financial results that indicateddouble-digit increases in both net income and revenues.For the
Nuclear medicine vendor ADAC Laboratories enjoyed a banner firstquarter of fiscal 1997 (end-December). The Milpitas, CA, firmlast week reported quarterly financial results that indicateddouble-digit increases in both net income and revenues.
For the period, ADAC reported revenues of $68.4 million, a 24%increase over the $55 million in sales reported for the firstquarter of 1996. Net income grew 44% to $5.1 million, comparedwith $3.5 million in the same period of 1996. ADAC also reportedrecord bookings of $82 million, adding $13 million to its backlog.
ADAC said the revenue growth was due to a 10% increase in servicerevenue and a 30% increase in product revenue. Product gross marginsgrew 3.7% to 41.8% in the period. ADAC also began volume shipmentsof its Molecular Coincidence Detection (MCD) high-energy imagingtechnique in the quarter.
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
